Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2007

Compendia and Ingenuity Integrate Technologies to Enhance Cancer Research

  • Compendia Bioscience (www.compendiabio.com) and Ingenuity Systems (www.ingenuity.com) decided to integrate their flagship products Oncomine™ Professional and Ingenuity Pathways Analysis (IPA). The resulting products will allow users to navigate directly from cancer gene signatures discovered in Oncomine Professional to the curated pathway information available on IPA. Oncomine Professional is a compendium of transcriptome profiles coupled with analysis functions and a web application for data mining and visualization. Ingenuity Pathways Analysis is a software application that enables identification of biological mechanisms, pathways, and functions.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »